MedTrace Logo

Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression

NCT03525665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2020-02-06

No results posted yet for this study

Summary

The study is designed as a retrospective analysis of patients with relapsed/refractory FL identified by the hematological centers of Italy.

Conditions

Interventions

OTHER

Metabolic activity measured by FDG-PET

To evaluate whether metabolic activity measured by FDG-PET (SUV max) at time of relapse is predictive of patient's outcome.

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Stefano Luminari · Ematologia - AO Arcispedale Santa Maria Nuova - IRCCS

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2019-12-30
Completion
2019-12-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03525665 on ClinicalTrials.gov